These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35650236)

  • 1. Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease.
    Nishiwaki H; Ito M; Hamaguchi T; Maeda T; Kashihara K; Tsuboi Y; Ueyama J; Yoshida T; Hanada H; Takeuchi I; Katsuno M; Hirayama M; Ohno K
    NPJ Parkinsons Dis; 2022 Jun; 8(1):65. PubMed ID: 35650236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder.
    Nishiwaki H; Hamaguchi T; Ito M; Ishida T; Maeda T; Kashihara K; Tsuboi Y; Ueyama J; Shimamura T; Mori H; Kurokawa K; Katsuno M; Hirayama M; Ohno K
    mSystems; 2020 Dec; 5(6):. PubMed ID: 33293403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis of Gut Dysbiosis in Parkinson's Disease.
    Nishiwaki H; Ito M; Ishida T; Hamaguchi T; Maeda T; Kashihara K; Tsuboi Y; Ueyama J; Shimamura T; Mori H; Kurokawa K; Katsuno M; Hirayama M; Ohno K
    Mov Disord; 2020 Sep; 35(9):1626-1635. PubMed ID: 32557853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
    Skorvanek M; Martinez-Martin P; Kovacs N; Rodriguez-Violante M; Corvol JC; Taba P; Seppi K; Levin O; Schrag A; Foltynie T; Alvarez-Sanchez M; Arakaki T; Aschermann Z; Aviles-Olmos I; Benchetrit E; Benoit C; Bergareche-Yarza A; Cervantes-Arriaga A; Chade A; Cormier F; Datieva V; Gallagher DA; Garretto N; Gdovinova Z; Gershanik O; Grofik M; Han V; Huang J; Kadastik-Eerme L; Kurtis MM; Mangone G; Martinez-Castrillo JC; Mendoza-Rodriguez A; Minar M; Moore HP; Muldmaa M; Mueller C; Pinter B; Poewe W; Rallmann K; Reiter E; Rodriguez-Blazquez C; Singer C; Tilley BC; Valkovic P; Goetz CG; Stebbins GT
    Mov Disord Clin Pract; 2017; 4(4):536-544. PubMed ID: 30363418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut bacterial profiles in Parkinson's disease: A systematic review.
    Li Z; Liang H; Hu Y; Lu L; Zheng C; Fan Y; Wu B; Zou T; Luo X; Zhang X; Zeng Y; Liu Z; Zhou Z; Yue Z; Ren Y; Li Z; Su Q; Xu P
    CNS Neurosci Ther; 2023 Jan; 29(1):140-157. PubMed ID: 36284437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features.
    Zhang F; Yue L; Fang X; Wang G; Li C; Sun X; Jia X; Yang J; Song J; Zhang Y; Guo C; Ma G; Sang M; Chen F; Wang P
    Parkinsonism Relat Disord; 2020 Dec; 81():84-88. PubMed ID: 33099131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson's Disease.
    Chen SJ; Chen CC; Liao HY; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
    J Parkinsons Dis; 2022; 12(4):1219-1230. PubMed ID: 35342048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson's Disease.
    Cerroni R; Pietrucci D; Teofani A; Chillemi G; Liguori C; Pierantozzi M; Unida V; Selmani S; Mercuri NB; Stefani A
    Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
    Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
    J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysbiosis of gut microbiota in a selected population of Parkinson's patients.
    Pietrucci D; Cerroni R; Unida V; Farcomeni A; Pierantozzi M; Mercuri NB; Biocca S; Stefani A; Desideri A
    Parkinsonism Relat Disord; 2019 Aug; 65():124-130. PubMed ID: 31174953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation.
    Kuai XY; Yao XH; Xu LJ; Zhou YQ; Zhang LP; Liu Y; Pei SF; Zhou CL
    Microb Cell Fact; 2021 May; 20(1):98. PubMed ID: 33985520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and intestinal dysbiosis in Parkinson's disease.
    Berthouzoz E; Lazarevic V; Zekeridou A; Castro M; Debove I; Aybek S; Schrenzel J; Burkhard PR; Fleury V
    Rev Neurol (Paris); 2023 Nov; 179(9):937-946. PubMed ID: 36934020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colonic bacterial composition in Parkinson's disease.
    Keshavarzian A; Green SJ; Engen PA; Voigt RM; Naqib A; Forsyth CB; Mutlu E; Shannon KM
    Mov Disord; 2015 Sep; 30(10):1351-60. PubMed ID: 26179554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.
    Jackson H; Anzures-Cabrera J; Taylor KI; Pagano G; ;
    Front Neurosci; 2021; 15():765765. PubMed ID: 34966256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation.
    Romano S; Savva GM; Bedarf JR; Charles IG; Hildebrand F; Narbad A
    NPJ Parkinsons Dis; 2021 Mar; 7(1):27. PubMed ID: 33692356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale.
    Stebbins GT; Goetz CG; Burn DJ; Jankovic J; Khoo TK; Tilley BC
    Mov Disord; 2013 May; 28(5):668-70. PubMed ID: 23408503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease.
    Shin C; Lim Y; Lim H; Ahn TB
    Mov Disord; 2020 Jun; 35(6):1021-1027. PubMed ID: 32154946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 20. Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease.
    Vascellari S; Palmas V; Melis M; Pisanu S; Cusano R; Uva P; Perra D; Madau V; Sarchioto M; Oppo V; Simola N; Morelli M; Santoru ML; Atzori L; Melis M; Cossu G; Manzin A
    mSystems; 2020 Sep; 5(5):. PubMed ID: 32934117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.